NewsNation on MSN
Pancreatic cancer shows nearly double overall survival rate in trial
The company reports the drug showed “clinically meaningful improvements” in overall survival ...
Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.
Trends in incidence and survival in anal adenocarcinoma: A SEER study of racial and age disparities.
Trends and disparities in palliative care utilization among patients with anal cancer: A ten-year retrospective study. This table summarizes the key trends in anal adenocarcinoma incidence and ...
Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with surgically treated renal cell carcinoma (RCC).
PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study Using SEER 22 data, we analyzed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results